Category: nuclear imaging
Detectnet (copper Cu 64 dotatate injection) Now Included in NCCN Guidelines® for Neuroendocrine Tumors
The newest FDA-approved PET imaging agent for neuroendocrine tumors — DetectnetTM (copper Cu 64 Dotate injection) — is now included in the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology – Neuroendocrine…
READ MORE
3rd Theranostics World Congress Offers Free Patient Program on March 14
Johns Hopkins University in Baltimore, Maryland will be the site of the 3rd Theranostics World Congress on Ga-68 & PRRT from March 12-14, 2015. Co-sponsored by the Society of Nuclear Medicine and Molecular Imaging and Johns Hopkins Medicine, the…
READ MORE
Carcinoid Cancer Foundation Awards Grant to Stanford University
The Carcinoid Cancer Foundation in White Plains, New York has awarded a grant of more than $65,000.00 to Stanford University in California to expand access to its Gallium-68 (Ga-68) DOTA-TATE PET/CT program for carcinoid and neuroendocrine tumor (NET)…
READ MORE
Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging 2014 Meeting
Josh Mailman, President of the NorCal CarciNET Community and Chair of the Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day on June…
READ MORE
Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging Patient Program
Josh Mailman, President of the NorCal CarciNET support group and Chair of the Patient Advocate Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day …
READ MORE
Excel Diagnostics and Nuclear Oncology Center Selected For New Investigational PRRT Treatment and Gallium Scan for Carcinoid and Neuroendocrine Tumor Patients
For carcinoid, pancreatic neuroendocrine tumor, and other NET cancer patients seeking the most advanced nuclear medicine opportunities in the United States, Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, in collaboration with…
READ MORE
2nd World Congress on Ga-68, Molecular Imaging & Targeted Radionuclide Therapy
Chandigarh, India will be the site of the 2nd World Congress on Ga-68 (Generators and Novel Radiopharmaceuticals), Molecular Imaging (PET/CT), Targeted Radionuclide Therapy and Dosimetry: On the Way to Personalized Medicine from February 28 through…
READ MORE
Archived Neuroendocrine Tumor Webinar by Dr. Eric Liu Now Available
Dr. Eric H. Liu, Director of the Neuroendocrine Center and Director of Surgical Services at Vanderbilt University Medical Center in Tennessee, presented a live webinar on August 22, 2012 entitled Imaging of Neuroendocrine Tumors and Obstacles to Diagnosis.…
READ MORE
Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community
The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100 abstracts on carcinoid…
READ MORE
1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)
Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin analogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to …
READ MORE
